Skip to content Skip to footer
Subscribe Now
NEWS

Lupin and Tenpoint Therapeutics Partner to Commercialize YUVEZZI in Key European Markets for Presbyopia

Shots: Lupin, through its wholly owned subsidiary VISUfarma B.V., entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia in the European Union, United Kingdom, Switzerland, Norway, and Iceland Under the agreement, VISUfarma will hold exclusive rights…
1 hour ago

Read more

NEWS

Biocon Biologics Inks Settlement and Licensing Deal with Regeneron and Bayer for Worldwide Commercialization of Yesafili (Biosimilar, Eylea) 

Shots:  Biocon Biologics has signed a settlement and license agreement with Regeneron and Bayer for Yesafili (Biosimilar, Eylea) in the EU and globally, following a prior US and Canada settlement  Biocon Biologics, Regeneron, and Bayer settled all pending litigation, allowing Yesafili’s UK launch in Jan’26 and other countries by Mar’26 or earlier. YESAFILI launched in Canada in 2024, and US market entry secured in April…
December 13, 2025

Read more